| 产品描述: | PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively |
| 靶点: |
MIC: 0.3 µM (MSSA), 0.3-1 µM (MRSA), 0.3 µM (VISA) |
| 体内研究: |
The in vivo efficacy of PK150 against methicillin-sensitive S. aureus (MSSA) (strain SH1000) is demonstrated in a murine bloodstream infection model. PK150 (20 mg/kg; p.o.) significantly reduces bacterial loads in the liver and heart.
PK150 (10 and 20mg/kg orally; or 10mg/kg intravenously) shows no obvious signs of toxicity in mice. Higher i.v. dosing of 20mg/kg results in severe toxic effects and is thus avoided for subsequent therapeutic models. Animal Model: Pathogen-free 9-week old female C57BL/6J mice Dosage:20 mg/kg Administration:Administered p.o. Result:Bacterial loads in the liver and heart were both significantly reduced by approximately 100-fold. Animal Model: Outbred male CD-1 mice, 4 weeks old Dosage:10 and 20 mg/kg (Pharmacokinetic Analysis) Administration:Administered by intragastric gavage at 10 and 20 mg/kg or intravenously at 10 mg/kg Result:Oral bioavailability was approximately 63% and the mean residence time was slightly enhanced via this administration route.T1/2=11.69±1.5, 9.67±0.2, and 9.37±0.5 hours for 10 mg/kg i.v., 10 mg/kg p.o., and 20 mg/kg p.o., respectively. |
| 参考文献: |
1. Le P, et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat Chem. 2019 Dec 16. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.534 ml |
12.668 ml |
25.337 ml |
| 5 mM |
0.507 ml |
2.534 ml |
5.067 ml |
| 10 mM |
0.253 ml |
1.267 ml |
2.534 ml |
| 50 mM |
0.051 ml |
0.253 ml |
0.507 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |